OverviewSuggest Edit

Vir Biotechnology is a clinical-stage immunology company focused on finding solutions to treat and prevent serious infectious diseases. The company brings together innovations with scientific expertise and management to take on some of the most infectious diseases for which solutions are non-existent or inadequate. Vir Biotechnology seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions.

TypePublic
Founded2016
HQSan Francisco, CA, US
Websitevir.bio
Employee Ratings3.9

Latest Updates

Employees (est.) (Sept 2019)217(+6%)
Job Openings52
Revenue (FY, 2020)$76.4 M(+844%)
Share Price (Jan 2022)$31.4(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Vir Biotechnology

George Scangos

George Scangos

President, Chief Executive Officer and Director
Aine Hanly

Aine Hanly

Chief Technology Officer
Lynne Krummen

Lynne Krummen

Senior Vice President, Regulatory and Development Program Leadership and Management
Howard Horn

Howard Horn

CFO
Antonio Lanzavecchia

Antonio Lanzavecchia

Senior Vice President and Senior Research Fellow
Bolyn Hubby

Bolyn Hubby

Chief Corporate Affairs Officer
Show more

Vir Biotechnology Office Locations

Vir Biotechnology has offices in San Francisco, Cambridge, Portland and Bellinzona
San Francisco, CA, US (HQ)
499 Illinois St, San Francisco
Cambridge, MA, US
625 Massachusetts Ave #143
Portland, OR, US
4640 SW Macadam Ave #200B
Bellinzona, CH
Via dei Gaggini 3
Show all (4)

Vir Biotechnology Financials and Metrics

Vir Biotechnology Revenue

Vir Biotechnology's revenue was reported to be $76.37 m in FY, 2020
USD

Net income (Q2, 2021)

61.8m

Market capitalization (25-Jan-2022)

4.3b

Closing stock price (25-Jan-2022)

31.4

Cash (31-Dec-2020)

436.6m

EV

3.9b
Vir Biotechnology's current market capitalization is $4.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.7m10.7m8.1m76.4m

Revenue growth, %

294%

General and administrative expense

21.7m29.1m37.6m70.9m

R&D expense

62.5m100.2m148.5m302.4m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q2, 2021

Revenue

1.4m5.7m67.0m

General and administrative expense

9.2m12.6m16.4m

R&D expense

39.9m65.0m79.7m

Operating expense total

49.1m77.6m96.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

187.9m47.6m109.3m436.6m

Prepaid Expenses

13.4m27.5m

Current Assets

192.4m117.8m403.0m772.4m

PP&E

5.1m12.3m16.3m17.9m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

80.7m93.7m168.4m371.8m

Prepaid Expenses

8.7m12.8m15.4m

Current Assets

377.4m337.7m377.5m578.8m

PP&E

15.4m15.4m16.2m16.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(69.9m)(115.9m)(174.7m)(298.7m)

Depreciation and Amortization

255.0k1.6m4.5m5.4m

Accounts Payable

2.0m1.5m964.0k(790.0k)

Cash From Operating Activities

(66.4m)(94.1m)(129.6m)(190.9m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q2, 2021

Net Income

(56.0m)(62.6m)(110.9m)(77.2m)(108.4m)(107.1m)

Depreciation and Amortization

589.0k1.5m3.4m1.3m612.0k2.5m

Accounts Payable

1.3m(833.0k)428.0k12.9m(1.3m)4.9m

Cash From Operating Activities

(30.0m)(53.8m)(90.7m)(48.4m)(59.0m)50.5m
USDFY, 2017

Revenue/Employee

64.5k

Financial Leverage

-3.7 x
Show all financial metrics

Vir Biotechnology Operating Metrics

Oct, 2019

Patents (US)

1

Phase I Trials Products

1

Phase II Trials Products

1

Pre-Clinical Phase Products

3
Show all operating metrics

Vir Biotechnology Acquisitions / Subsidiaries

Company NameDateDeal Size
Statera Health, LLCFebruary 28, 2018$1.7 m
Agenovir CorporationJanuary 31, 2018$15.3 m
Humabs BioMed SAAugust 31, 2017$42.3 m
TomegaVax, Inc.September 30, 2016$5.2 m
VirAb, Inc.
Vir AU Biotechnology Pty Ltd.
Vir Predictive Medicine, Inc.

Vir Biotechnology Revenue Breakdown

Embed Graph

Vir Biotechnology revenue breakdown by business segment: 91.9% from Grant Revenue and 8.1% from Contract Revenue

Vir Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Vir Biotechnology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Vir Biotechnology Online and Social Media Presence

Embed Graph

Vir Biotechnology News and Updates

Thinking about trading options or stock in KB Home, Vir Biotechnology, Applied Materials, Take-Two Interactive, or Nio?

NEW YORK, Jan. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KBH, VIR, AMAT, TTWO, and NIO. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about trading options or stock in Moderna, Vir Biotechnology, BioNTech, Cerner Corp, or Apple?

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VIR, BNTX, CERN, and AAPL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about trading options or stock in FedEx, Vir Biotechnology, AT&T, Roku, or Rivian Automotive?

NEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FDX, VIR, T, ROKU, and RIVN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about trading options or stock in Apple, Vir Biotechnology, Centene Corp, Pfizer, or GameStop?

NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, VIR, CNC, PFE, and GME. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about trading options or stock in Vir Biotechnology, Pfizer, Apple, Tesla, or AMC Entertainment?

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, PFE, AAPL, TSLA, and AMC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
Show more

Vir Biotechnology Blogs

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference Content Import Tue, 01/04/2022 - 16:03 Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference 01/04/22 at 4:02 PM EST This release is a backfill from a News Wi…

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies Content Import Tue, 12/14/2021 - 16:40 Preclinical Data Highlight the S…

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results Content Import Thu, 11/04/2021 - 16:09 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results 11/04/21 at 4:05 PM EDT This releas…

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021 Content Import Thu, 10/21/2021 - 16:07 Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021 10/21/21…

Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference

Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference Content Import Thu, 09/30/2021 - 16:06 Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference 09/30/21 at 4:05…

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Content Import Tue, 09/07/2021 - 16:07 Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference 09/07/21 at 4:05 PM EDT Thi…
Show more

Vir Biotechnology Frequently Asked Questions

  • When was Vir Biotechnology founded?

    Vir Biotechnology was founded in 2016.

  • Who are Vir Biotechnology key executives?

    Vir Biotechnology's key executives are George Scangos, Aine Hanly and Lynne Krummen.

  • How many employees does Vir Biotechnology have?

    Vir Biotechnology has 217 employees.

  • What is Vir Biotechnology revenue?

    Latest Vir Biotechnology annual revenue is $76.4 m.

  • What is Vir Biotechnology revenue per employee?

    Latest Vir Biotechnology revenue per employee is $351.9 k.

  • Who are Vir Biotechnology competitors?

    Competitors of Vir Biotechnology include AlloVir, Memo Therapeutics and Altis Biosystems.

  • Where is Vir Biotechnology headquarters?

    Vir Biotechnology headquarters is located at 499 Illinois St, San Francisco, San Francisco.

  • Where are Vir Biotechnology offices?

    Vir Biotechnology has offices in San Francisco, Cambridge, Portland and Bellinzona.

  • How many offices does Vir Biotechnology have?

    Vir Biotechnology has 4 offices.